Sodium –glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials

ConclusionSGLT2i as an add-on therapy to insulin improved glycemic control and body weight and decreased the required dose of insulin without increasing the risk of hypoglycemia. However, after 6  months the benefits of SGLT2is on glycemic control may weaken and the risks of GTIs and DKA increased.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research